Clinical Research Informer

p applicant Abbvie

Phase 3 Maintenance Results Show Patients with Crohn’s Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year

The Pharma Data

JUNE 18, 2021

After one year, 47 percent of patients receiving risankizumab 360 mg achieved endoscopic response compared with 22 percent of patients in the induction-only control group (p<0.001). analysis plan), with 52 percent on risankizumab 360 mg achieving clinical remission versus 41 percent in the induction-only control group (p<0.01).

Trials

Trials Development Clinical Trials Clinical Trials

AbbVie’s Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for.

The Pharma Data

OCTOBER 29, 2021

AbbVie moment blazoned top- line results from two Phase 3 clinical trials, Study3111-301-001 and Study3111-302-001, assessing the efficacity and safety of cariprazine (VRAYLAR ®) as an spare treatment for cases with major depressive complaint (MDD). Cariprazine is beingco-developed by AbbVie and Gedeon Richter Plc. mg/ day or3.0

In-Vitro

In-Vitro Clinical Trials Clinical Trials Trials

Join 32,000+

Insiders

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients

The Pharma Data

FEBRUARY 22, 2021

AbbVie (NYSE: ABBV) today announced that upadacitinib (45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all ranked secondary endpoints in the Phase 3 induction study, U-ACCOMPLISH. All primary and ranked secondary endpoints achieved p-values of <0.001 versus placebo.

Medicine

Medicine Development Drugs Trials

AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn’s Disease

The Pharma Data

JUNE 18, 2021

All differences between the overall risankizumab dose groups and placebo are statistically significant, with p-values <0.001. Risankizumab (SKYRIZI) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally. About AbbVie in Gastroenterology.

Clinical Trials

Clinical Trials Clinical Trials Trials Development

New Data Shows AbbVie’s VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment

The Pharma Data

JUNE 18, 2021

vice president and head, global oncology development, AbbVie. VENCLYXTO/VENCLEXTA is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. 1.35]; P=0.49). VENCLYXTO is being developed by AbbVie and Roche.

Medicine

Medicine HR Trials Production

U.S. FDA Accepts AbbVie’s New Drug Application for Atogepant for the Preventive Treatment of Migraine

The Pharma Data

MARCH 30, 2021

2] – The atogepant application demonstrates AbbVie’s longstanding commitment to providing multiple migraine treatment options, including BOTOX® (onabotulinumtoxinA), a preventive treatment for those with chronic migraine, and UBRELVY® (ubrogepant), an acute treatment for adults with migraine. . across all doses vs. 0.5%

Botox

Botox Drugs Doctors Doctor

AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition

The Pharma Data

JULY 25, 2021

Allergan, an AbbVie company, today announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. vice president, global therapeutic area head, eye care, AbbVie.

Production

Production Development Drugs Trials

Combating antimicrobial resistance with a viable alternative to traditional antibiotics

pharmaphorum

JUNE 9, 2022

Healthcare executive with 29-years of Biopharmaceutical experience working with Global leaders such as Abbott, Novo Nordisk and AbbVie. Micreos Pharmaceuticals develops new biological therapies based on the targeted killing of unwanted bacteria, which has medical potential in a broad range of applications. Herpers, P.

Bacteria

Bacteria Development In-Vitro Drugs

AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) in Combination with a Hypomethylating Agent for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

The Pharma Data

JUNE 18, 2021

May 25, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) announced today that the European Commission (EC) has approved VENCLYXTO ® (venetoclax) in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.

Trials

Trials Clinical Trials Clinical Trials Medicine

AbbVie Receives Positive CHMP Opinion for VENCLYXTO® (venetoclax) as a Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

The Pharma Data

APRIL 28, 2021

vice president and global head of oncology development at AbbVie. ” Venetoclax is being developed by AbbVie and Roche. . ” Venetoclax is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.

Trials

Trials Medicine Clinical Trials Clinical Trials

CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL)

The Pharma Data

JUNE 18, 2021

This rate was higher than the 37% minimum meaningful rate study assumption (P<0.0001). “Combining our novel therapies to deliver a new potential treatment is an example of AbbVie’s innovative approach to identify options for difficult-to-treat blood cancers, like CLL,” said Mohamed Zaki , M.D., NORTH CHICAGO, Ill.

Medicine

Medicine Production FDA Approval Trials

IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study

The Pharma Data

JUNE 18, 2021

The study met its primary endpoint of superior progression-free survival (PFS) as assessed by an independent review committee (IRC) with a HR 0.216 (95% CI, 0.131-0.357; p < 0.0001), demonstrating a reduction in the risk of disease progression or death for I+V of approximately 78% compared to C+O. vs. 11.4%) (p < 0.0001).

Medicine

Medicine Production FDA Approval Trials

Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)

The Pharma Data

JUNE 18, 2021

June 4, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV), today announced extended long-term data from the Phase 3 RESONATE-2 study ( PCYC-1115/1116 ) evaluating single-agent IMBRUVICA (ibrutinib) versus chlorambucil with up to seven years of follow-up in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

FDA Approval

FDA Approval Medicine Development Trials

Phase 3 Maintenance Results Show Patients with Crohn’s Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year

AbbVie’s Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for.

Trending Sources

Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients

AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn’s Disease

New Data Shows AbbVie’s VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment

U.S. FDA Accepts AbbVie’s New Drug Application for Atogepant for the Preventive Treatment of Migraine

AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition

Combating antimicrobial resistance with a viable alternative to traditional antibiotics

AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) in Combination with a Hypomethylating Agent for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

AbbVie Receives Positive CHMP Opinion for VENCLYXTO® (venetoclax) as a Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL)

IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study

Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)

Stay Connected